Minor
Suspected
Description
Both oseltamivir carboxylate and methotrexate rely on renal tubular secretion via OAT transporters; theoretically, competition could reduce elimination of either drug, though clinical evidence of a significant interaction is limited.
Mécanisme
Oseltamivir carboxylate and methotrexate are both substrates of OAT1 and OAT3 renal transporters; co-administration could theoretically inhibit secretion of both drugs.
Signification clinique
No clinical cases of significant interaction have been published; probenecid (a well-documented OAT inhibitor) doubles oseltamivir exposure, suggesting the pathway is pharmacologically relevant.
Prise en charge
Routine monitoring is sufficient; no dose adjustment required in patients with normal renal function.